Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial-Reference-Cited by-同舟云学术

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Published:2016-07 Issue:10041 Volume:388 Page:239-247
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Porter Duncan,van Melckebeke Jurgen,Dale James,Messow C Martina,McConnachie Alexander,Walker Andrew,Munro Robin,McLaren John,McRorie Euan,Packham Jon,Buckley Christopher D,Harvie John,Taylor Peter,Choy Ernest,Pitzalis Costantino,McInnes Iain B

Publisher

Elsevier BV

Subject

General Medicine

Reference19 articles.

1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update;Smolen;Ann Rheum Dis,2014

2. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks;Cohen;Arthritis Rheum,2006

3. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis;Buch;Ann Rheum Dis,2011

4. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX Study;Keystone;J Rheumatol,2012

5. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial;Emery;Arthritis Rheum,2006

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial;RMD Open;2024-08

2. The role of anti-citrullinated protein antibody in pathogenesis of RA;Clinical and Experimental Medicine;2024-07-08

3. Systematic review and meta-analysis for the 2024 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis;Modern Rheumatology;2024-05-30

4. Clinical practice guidelines for the early detection, diagnosis, treatment, and follow-up of patients with rheumatoid arthritis. Colombian Association of Rheumatology, 2022;Revista Colombiana de Reumatología (English Edition);2024-04

5. Treat-to-target vs fixed interval retreatment strategy with rituximab in rheumatoid arthritis: a retrospective cohort study;Rheumatology International;2024-01-29